COMMUNIQUÉS West-GlobeNewswire

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
16/04/2025
Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for [...]
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/04/2025
WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
Tilray Brands Ranks #4 on the Brewers Association List of Top Producing Craft Brewers in the United States
16/04/2025
Tilray Beverages Climbs to #4! Cheers to Ranking Among the Top Craft Brewers in the U.S.! NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Tilray Beverages, a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is [...]
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
16/04/2025
Dr. Taub’s pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a [...]
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
16/04/2025
Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced [...]
Cannara Biotech Inc. to Announce Fiscal Q2 2025 Financial Results on April 28, 2025
16/04/2025
MONTREAL, April 16, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Cannara Biotech Inc. annoncera ses résultats financiers pour le deuxième trimestre de l'exercice 2025 le 28 avril 2025
16/04/2025
MONTRÉAL, 16 avr. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara » , « la Société » , « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis [...]
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
16/04/2025
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of [...]
Spectral Medical Completes Tigris Trial Enrollment
16/04/2025
157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “ [...]
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
16/04/2025
LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced [...]
Sustanon 250: Sustanon Testosterone Cycle Results, Buy Top Sustanon 250 Injection Alternative For Bodybuilding By CrazyBulk
16/04/2025
Sustanon 250 Injections and Sustanon Testosterone are testosterone boosters. According to the maker, they are safe to use and employ natural ingredients to boost overall health and wellness. Albany, New York, April 16, [...]
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
16/04/2025
RECORDATI: FDA GRANTS ISTURISA ® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA ® is a cortisol synthesis inhibitor that blocks the [...]
Glutathione Tablets: RediClinic Offers 20% Off on Pure Japanese Glutathione Tablets for Skin Whitening
16/04/2025
New York, April 15, 2025 (GLOBE NEWSWIRE) -- Glutathione Tablets: RediClinic Offers 20% Off on Pure Japanese Glutathione Tablets for Skin Whitening Rediclinic glutathione tablets Content promoted by Branding Ex solution [...]
Prime Biome (Updated 2025): A Comprehensive Review of the Groundbreaking Skin-Gut Axis Supplement
16/04/2025
Clinically Inspired Gut-Skin Axis Supplement Prime Biome Faces Real Consumer Feedback and Scientific Scrutiny—Here’s What the Data and Verified Users Reveal in 2025 ST. PETERSBURG, Fla., April 16, 2025 (GLOBE NEWSWIRE [...]
Conditional Issuance of Shares
16/04/2025
INSIDE INFORMATION REGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), [...]
Émission Conditionnelle d’Actions
16/04/2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Émission Conditionnelle d’Actions Mont-Saint-Guibert, Belgique – le 16 avril 2025, 8:00h CET / 2:00h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” ou la “ [...]
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
16/04/2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Santhera shares updates on commercial rollout of AGAMREE®
16/04/2025
Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding from [...]
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond
16/04/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 16, 2025 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority ( obere kantonale Nachlassbehörde [...]

Pages